These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32602240)

  • 1. Detailed optical coherence tomography angiographic short-term response of type 3 neovascularization to combined treatment with photodynamic therapy and intravitreal bevacizumab.
    Smid LM; Vermeer KA; Wong KT; Martinez Ciriano JP; de Jong JH; Davidoiu V; de Boer JF; van Velthoven MEJ
    Acta Ophthalmol; 2021 Mar; 99(2):207-214. PubMed ID: 32602240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Effects in Retinal Angiomatous Proliferation Imaged with OCT Angiography.
    de Jong JH; Braaf B; Amarakoon S; Gräfe M; Yzer S; Vermeer KA; Missotten T; de Boer JF; van Velthoven MEJ
    Ophthalmologica; 2019; 241(3):143-153. PubMed ID: 30227415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.
    Lim JY; Lee SY; Kim JG; Lee JY; Chung H; Yoon YH
    Acta Ophthalmol; 2012 Feb; 90(1):61-7. PubMed ID: 20337606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.
    Saito M; Iida T; Kano M
    Jpn J Ophthalmol; 2013 Mar; 57(2):211-20. PubMed ID: 23208024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Identification of Choroidal Neovascularization Activity by Location and Quantification of Abnormal Fluid Under Anti-Vascular Endothelial Growth Factor Therapy.
    Farinha C; Santos T; Santos AR; Lopes M; Alves D; Silva R; Cunha-Vaz J
    Retina; 2020 May; 40(5):881-890. PubMed ID: 30689620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study.
    Saviano S; Leon PE; Mangogna A; Tognetto D
    Digit J Ophthalmol; 2016; 22(2):46-53. PubMed ID: 27582675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive factors of age-related macular degeneration with poor response to three loading doses of anti-vascular endothelial growth factor.
    Sariyeva Ismayilov A; Duru Y; Çağlar T; Erseven C; Ulusoy MO
    Int Ophthalmol; 2024 Jun; 44(1):264. PubMed ID: 38913217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.
    Shirakata Y; Shiragami C; Yamashita A; Nitta E; Fujiwara A; Shiraga F
    Jpn J Ophthalmol; 2012 Nov; 56(6):599-607. PubMed ID: 22990616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal Bevacizumab with or without Triamcinolone for Wet Age-related Macular Degeneration: Twelve-month Results of a Prospective, Randomized Investigation.
    Motarjemizadeh Q; Aidenloo NS; Abbaszadeh M; Sadrinia V
    Middle East Afr J Ophthalmol; 2018; 25(1):1-7. PubMed ID: 29899643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
    Karasu B; Gunay BO
    Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
    Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
    Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography.
    Shin JY; Woo SJ; Ahn J; Park KH
    Korean J Ophthalmol; 2013 Dec; 27(6):425-32. PubMed ID: 24311928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.
    Parodi MB; Iacono P; Papayannis A; Sheth S; Bandello F
    Arch Ophthalmol; 2010 Apr; 128(4):437-42. PubMed ID: 20142520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling neovascular age-related macular degeneration choroidal neovascularization lesion response to anti-vascular endothelial growth factor therapy using SSOCTA.
    Told R; Reiter GS; Mittermüller TJ; Schranz M; Reumueller A; Schlanitz FG; Weigert G; Pollreisz A; Sacu S; Schmidt-Erfurth U
    Acta Ophthalmol; 2021 Mar; 99(2):e240-e246. PubMed ID: 32706171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization.
    Ikuno Y; Nagai Y; Matsuda S; Arisawa A; Sho K; Oshita T; Takahashi K; Uchihori Y; Gomi F
    Am J Ophthalmol; 2010 Jan; 149(1):140-6. PubMed ID: 19846061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
    Saito M; Shiragami C; Shiraga F; Kano M; Iida T
    Am J Ophthalmol; 2010 Mar; 149(3):472-81.e1. PubMed ID: 20053392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
    el Matri L; Chebil A; Kort F; Bouraoui R; Baklouti K; Mghaieth F
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
    Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
    Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Ahadi H
    Eur J Ophthalmol; 2008; 18(2):297-300. PubMed ID: 18320527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.